Metropolitan Life Insurance Co. NY Sells 309,952 Shares of Eli Lilly and Co (NYSE:LLY)

Metropolitan Life Insurance Co. NY trimmed its position in Eli Lilly and Co (NYSE:LLY) by 61.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 193,537 shares of the company’s stock after selling 309,952 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Eli Lilly and were worth $16,346,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. YorkBridge Wealth Partners LLC lifted its stake in Eli Lilly and by 0.8% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after purchasing an additional 24 shares during the last quarter. Princeton Portfolio Strategies Group LLC lifted its stake in Eli Lilly and by 0.3% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 17,860 shares of the company’s stock worth $1,470,000 after purchasing an additional 53 shares during the last quarter. Ironwood Investment Counsel LLC lifted its stake in Eli Lilly and by 1.4% during the second quarter. Ironwood Investment Counsel LLC now owns 7,300 shares of the company’s stock worth $601,000 after purchasing an additional 100 shares during the last quarter. Clear Perspective Advisors LLC lifted its stake in shares of Eli Lilly and by 2.2% in the 2nd quarter. Clear Perspective Advisors LLC now owns 4,940 shares of the company’s stock valued at $407,000 after acquiring an additional 107 shares during the last quarter. Finally, Keel Point LLC lifted its stake in shares of Eli Lilly and by 2.6% in the 2nd quarter. Keel Point LLC now owns 7,765 shares of the company’s stock valued at $639,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 77.63% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of LLY stock opened at $76.85 on Friday. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market cap of $86,135.91, a PE ratio of 17.96, a P/E/G ratio of 1.43 and a beta of 0.26. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the business earned $0.95 EPS. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. equities analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

A number of brokerages have recently commented on LLY. BMO Capital Markets reiterated a “sell” rating and issued a $74.00 price target on shares of Eli Lilly and in a research note on Wednesday. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Tuesday, April 3rd. Jefferies Group restated a “buy” rating and issued a $91.00 price objective on shares of Eli Lilly and in a report on Friday, March 23rd. TheStreet downgraded Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Finally, Bank of America decreased their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Eli Lilly and has an average rating of “Hold” and a consensus target price of $92.84.

In other news, CFO Joshua L. Smiley sold 3,000 shares of Eli Lilly and stock in a transaction on Friday, March 16th. The shares were sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the sale, the chief financial officer now directly owns 20,029 shares of the company’s stock, valued at approximately $1,586,296.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,261 shares of company stock valued at $1,225,085 over the last 90 days. Company insiders own 0.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Metropolitan Life Insurance Co. NY Sells 309,952 Shares of Eli Lilly and Co (NYSE:LLY)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/metropolitan-life-insurance-co-ny-cuts-holdings-in-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply